Mindray seals $35.5M deal for Dragonbio's orthopedics implant line

Six weeks after the initial announcement, Chinese device giant Mindray Medical ($MR) has completed its $35.5 million bid to buy Wuhan Dragonbio Surgical Implant Co.'s orthopedics business. Dragonbio makes spine, joint, and trauma-related surgical orthopedics implants. The space represents a major growth area for Mindray and others. Frost & Sullivan estimated, for example, that the Chinese orthopedics market was worth $1.1 billion in 2010. Add to that a projected 18% annual growth rate, and Mindray will be off and running. Release

Suggested Articles

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.

The FDA has authorized its first COVID-19 antibody test for use in doctors' offices, urgent care centers and emergency rooms.

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.